Literature DB >> 10733432

Endothelins are potent vasoconstrictors, and much more besides.

G A Gray1, B Battistini, D J Webb.   

Abstract

Mesh:

Substances:

Year:  2000        PMID: 10733432     DOI: 10.1016/s0165-6147(99)01431-5

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


× No keyword cloud information.
  8 in total

1.  Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey.

Authors:  S A Douglas; A C Sulpizio; V Piercy; H M Sarau; R S Ames; N V Aiyar; E H Ohlstein; R N Willette
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 2.  Endothelin receptor antagonists and cardiovascular diseases of aging.

Authors:  M P Love; J J McMurray
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 3.  Air Pollution-Induced Vascular Dysfunction: Potential Role of Endothelin-1 (ET-1) System.

Authors:  Jordan Finch; Daniel J Conklin
Journal:  Cardiovasc Toxicol       Date:  2016-07       Impact factor: 3.231

4.  Localization and function of ET-1 and ET receptors in small arteries post-myocardial infarction: upregulation of smooth muscle ET(B) receptors that modulate contraction.

Authors:  G A Gray; E J Mickley; D J Webb; P E McEwan
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

Review 5.  Cannabinoids and glaucoma.

Authors:  I Tomida; R G Pertwee; A Azuara-Blanco
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638

6.  Association of three polymorphisms in the gene coding for endothelin-1 with essential hypertension, overweight and smoking.

Authors:  Anna Vasku; Svatava Tschöplova; Jan Muzik; Miroslav Soucek; Jiri Vacha
Journal:  Exp Clin Cardiol       Date:  2002

7.  Intraocular pressure-lowering effect of oral paracetamol and its in vitro corneal penetration properties.

Authors:  Nabiel Mohamed; David Meyer
Journal:  Clin Ophthalmol       Date:  2013-01-30

8.  Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis.

Authors:  Lucy Kappes; Ruba L Amer; Sabine Sommerlatte; Ghada Bashir; Corinna Plattfaut; Frank Gieseler; Timo Gemoll; Hauke Busch; Abeer Altahrawi; Ashraf Al-Sbiei; Shoja M Haneefa; Kholoud Arafat; Lena F Schimke; Nadia El Khawanky; Kai Schulze-Forster; Harald Heidecke; Anja Kerstein-Staehle; Gabriele Marschner; Silke Pitann; Hans D Ochs; Antje Mueller; Samir Attoub; Maria J Fernandez-Cabezudo; Gabriela Riemekasten; Basel K Al-Ramadi; Otavio Cabral-Marques
Journal:  Sci Rep       Date:  2020-09-28       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.